Table 2.
Demographics
| rt-PA+Eptifibatide | rt-PA | P Value | |
|---|---|---|---|
| N | 101 | 25 | |
| Age, y, median (IQR) | 71.6 (58.1–81.5) | 75.5 (60.5–81.4) | 0.63 |
| Women, n (%) | 48 (47.5) | 12 (48.0) | 0.97 |
| Black, n (%) | 14 (13.9) | 2 (8.0) | 0.74 |
| Baseline NIHSS, median (IQR) | 12.0 (9.0–20.0) | 17.0 (11.0–22.0) | 0.11 |
| Baseline mRS (0–1) | 85 (84.2%) | 18 (72.0%) | 0.16 |
| Baseline systolic BP, median (IQR) | 155 (135–175) | 143 (136–159) | 0.22 |
| Baseline diastolic BP, median (IQR) | 84 (70–99) | 83 (74–90) | 0.64 |
| Prior stroke, n (%) | 14 (14.0) | 2 (8.0) | 0.52 |
| Diabetes mellitus, n (%) | 31 (30.7) | 9 (36.0) | 0.61 |
| Hypertension, n (%) | 84 (83.2) | 19 (76.0) | 0.41 |
| Coronary artery disease, n (%) | 12 (12.4) | 4 (16.0) | 0.74 |
| Atrial fibrillation, n (%), (history or initial EKG) | 36 (35.6) | 9 (36.0) | 0.97 |
| Antiplatelet use before stroke, n (%) | 43 (42.6) | 7 (28.0) | 0.18 |
| Anticoagulant use before stroke, n (%) | 7 (6.9) | 1 (4.0) | 1.00 |
| Current smoker, n (%) | 31 (31.0) | 7 (28.0 | 0.93 |
| Symptom onset to IV rt-PA, min, median (IQR) | 113 (99–135) | 129 (90–141) | 0.69 |
| IV rt-PA to eptifibatide or placebo, min, median (IQR) | 40 (33–44) | 43 (38–48) | 0.04 |
| Symptom onset to IV rt-PA, n (%) | 0.50 | ||
| <1 h | 1 (1.0) | 0 | |
| 1–2 h | 56 (55.4) | 11 (44.0) | |
| >2–3 h | 42 (41.6) | 13 (52.0) | |
| >3 h* | 2 (2.0) | 1 (4.0) |
Data presented as median (25th percentile–75th percentile). Wilcoxon rank sum or t test used to test difference between groups for interval variables, χ2, or Fisher exact test, as appropriate, for proportions.
BP indicates blood pressure; EKG, electrocardiogram; IQR, interquartile range; IV, intravenous; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; and rt-PA, recombinant tissue plasminogen activator.
*
All 3 subjects received rt-PA <3 h and 10 min from symptom onset.